Praxsyn Announces Official Name Change and New Trading Symbol PXYN

IRVINE, Calif., Sept. 5, 2014  -- Praxsyn Corporation (OTCQB:PXYN), a medication and service provider for medical practitioners, announced that it has received approval from the Financial Industry Regulatory Authority ("FINRA") for an official change in the name of the Company effective at the open of business on September 5, 2014. As previously announced, the Company changed its name to Praxsyn Corporation and will now trade under the symbol "PXYN".

Praxsyn Now Licensed to Dispense Medication in Twelve States

IRVINE, Calif., Sept. 4, 2014 -- Praxsyn Corporation (OTCQB:PXYN), today announced that its subsidiary, Mesa Pharmacy Inc., a medication and service provider for medical practitioners, is making progress towards its goal of dispensing its customized medications nationwide. The company is now licensed to dispense its medications in the following twelve states:

PRAXSYN CORP Files SEC form 10-Q, Quarterly Report Q2 2014

Form 10-Q for PRAXSYN CORP


19-Aug-2014

Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Statements Regarding Forward-Looking Statements

This Management's Discussion and Analysis of Financial Condition and Results Of Operation and other parts of this Form 10-Q contain forward-looking statements that involve risks and uncertainties. All forward-looking statements included in this Form 10-Q are based on information available to us on the date hereof, and except as required by law, we assume no obligation to update any such forward-looking statements. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth in the current report on the Form 8-K/A as filed with the Securities and Exchange Commission on July 16, 2014 and other filings with the SEC. The following should be read in conjunction with our condensed consolidated financial statements contained elsewhere in this report.

PRAXSYN CORP Files SEC form 10-Q, Quarterly Report Q1 2014

Form 10-Q for PRAXSYN CORP


25-Jul-2014

Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Statements Regarding Forward-Looking Statements

This Management's Discussion and Analysis of Financial Condition and Results Of Operation and other parts of this Form 10-Q contain forward-looking statements that involve risks and uncertainties. All forward-looking statements included in this Form 10-Q are based on information available to us on the date hereof, and except as required by law, we assume no obligation to update any such forward-looking statements. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth in the current report on the Form 8-K/A as filed with the Securities and Exchange Commission on July 16, 2014 and other filings with the SEC. The following should be read in conjunction with our condensed consolidated financial statements contained elsewhere in this report

Dollar amounts of $1.0 million or more are rounded to the nearest one tenth of a million; all other dollar amounts are rounded to the nearest one thousand and all percentages are stated to the nearest one tenth of one percent.

PRAXSYN CORP Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhib

Form 8-K/A for PRAXSYN CORP


16-Jul-2014

Completion of Acquisition or Disposition of Assets, Financial Statements and Exhib

Item 2.01 Completion of Acquisition or Disposition of Assets.

On March 31, 2014, Praxsyn closed an Agreement and Plan of Merger Agreement (the "APMA") with Pharmacy Development Corp., a California corporation ("PDC") whereby the Company acquired PDC through a forward triangular merger into the Company's wholly owned subsidiary PDC, Inc., a Nevada corporation in exchange for five hundred thousand (500,000) shares of the Company's Series D Convertible Preferred Stock (the "Series D Stock").

Pages